{"nctId":"NCT00461630","briefTitle":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","startDateStruct":{"date":"2007-01"},"conditions":["Cardiovascular Disease","Peripheral Arterial Disease","Diabetes Mellitus","Coronary Heart Disease"],"count":25673,"armGroups":[{"label":"ER niacin/laropiprant","type":"EXPERIMENTAL","interventionNames":["Drug: ER niacin/laropiprant","Drug: simvastatin","Drug: ezetimibe/simvastatin"]},{"label":"Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: simvastatin","Drug: ezetimibe/simvastatin"]}],"interventions":[{"name":"ER niacin/laropiprant","otherNames":["Tredaptive"]},{"name":"simvastatin","otherNames":["Zocor"]},{"name":"ezetimibe/simvastatin","otherNames":["Inegy","Vytorin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of myocardial infarction; or\n* Cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation)\n* Peripheral arterial disease (i.e. intermittent claudication or history of revascularisation); or\n* Diabetes mellitus with any of the above or with other evidence of symptomatic coronary heart disease (i.e. stable or unstable angina, or a history of coronary revascularisation or acute coronary syndrome).\n\nExclusion Criteria:\n\n* Age \\<50 or \\>80 years at invitation to Screening;\n* Less than 3 months since presentation with acute myocardial infarction, coronary syndrome or stroke (but such patients may be entered later, if appropriate);\n* Planned revascularisation procedure within 3 months after randomization (but such patients may be entered later, if appropriate);\n* Definite history of chronic liver disease, or abnormal liver function (i.e. Alanine transaminase (ALT) \\>1.5 times upper limit of normal (ULN). (Note: Patients with a history of acute hepatitis are eligible provided this ALT limit is not exceeded);\n* Breathlessness at rest for any reason;\n* Severe renal insufficiency (i.e. creatinine \\>200 Âµmol/L);\n* Evidence of active inflammatory muscle disease (e.g. dermatomyositis, polymyositis), or Creatine kinase (CK) \\>3 times upper limit of normal (3xULN);\n* Previous significant adverse reaction to a statin, ezetimibe, niacin or laropiprant;\n* Active peptic ulcer disease;\n* Concurrent treatment with:\n* fibric acid derivative (\"fibrate\")\n* niacin (nicotinic acid) at doses more than 100 mg daily\n* ezetimibe in combination with either simvastatin 80 mg, or atorvastatin 20-80 mg, or rosuvastatin 10-40 mg daily\n* any potent cytochrome P450 3A4 (CYP3A4) inhibitor, including: macrolide antibiotics (erythromycin, clarithromycin, telithromycin); systemic use of imidazole or triazole antifungals (e.g. itraconazole, ketoconazole); protease inhibitors (antiretroviral drugs for HIV infection); and nefazodone\n* ciclosporin\n* amiodarone\n* verapamil\n* danazol (Note: Patients who are temporarily taking such drugs may be re-screened when they discontinue them, if considered appropriate.);\n* Known to be poorly compliant with clinic visits or prescribed medication;\n* Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease, history of cancer or evidence of spread within last 5 years other than non-melanoma skin cancer, or recent history of alcohol or substance misuse)","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Vascular Event","description":"Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1696","spread":null},{"groupId":"OG001","value":"1758","spread":null}]}]}]},{"type":"SECONDARY","title":"Major Coronary Events","description":"Non-fatal myocardial infarction (MI) or coronary death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"668","spread":null},{"groupId":"OG001","value":"694","spread":null}]}]}]},{"type":"SECONDARY","title":"Stroke","description":"Fatal or non-fatal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"498","spread":null},{"groupId":"OG001","value":"499","spread":null}]}]}]},{"type":"SECONDARY","title":"Coronary or Non-coronary Revascularisation","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"807","spread":null},{"groupId":"OG001","value":"897","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"All-cause mortality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"798","spread":null},{"groupId":"OG001","value":"732","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7137,"n":12838},"commonTop":["Skin and subcutaneous tissue disorders","Gastrointestinal disorders","Musculoskeletal and connective tissue disorders","Vascular disorders","Metabolism and nutrition disorders"]}}}